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Isolated splenic metastasis is rare in colorectal 
cancer. Malign melanoma, breast and ovarian cancers 
are the most common solid tumors in which splenic 
metastasis occurs [1]. Isolated splenic metastasis may 
be synchronous or metachronous. The rates of iso-
lated splenic metastasis are reported as 4.4% for colon 
cancer and 1.6% for rectum cancer. It is ge nerally 
diagnosed while evaluating asymptomatic cancer 
patients with increasing levels of carcinoembryonic 
antigen (CEA). In this report, our aim is to report two 
cases with atypical metastasis.
Case 1. A 58-year old male patient was admitted to 
the hospital with ileus a year ago. Hemicolectomy was 
performed after the diagnosis of colon carcinoma. His-
topathology revealed colon adenocarcinoma without 
lymph node involvement (stage III). He was given adju-
vant 5-flurouracil (5-FU)-based chemotherapy. He had 
a CEA level elevation [4.62 ng/mL (N: 0–3.4)] in blood 
serum fifteen months after hemicolectomy without any 
evidence of local or distant metastasis on evaluation. 
However, a splenic mass was diagnosed 5 months 
later. Splenectomy was performed, and histopathology 
revealed the metastasis of colon adenocarcinoma in 
the spleen. A 3.5 x 3 x 2.5 cm size tumor was located 
just beneath the capsule of the spleen (Fig. 1, a, b). 
Chemotherapy which consisted of 5-FU, leucovorine 
(LV) and oxaliplatin (FOLFOX-4) was given. He had a 
second relapse in the splenic localization (5.5 x 3 cm) 
after 11 months of first relapse. An increased uptake of 
18-fluorodeoxyglucose (18-FDG) was observed only 
in this lesion with standardized uptake value (SUVmax) 
of 11.7 on 18-FDG-positron emission computerized 
tomography (18-FDG-PET-CT) (Fig. 2). Palliative che-
motherapy including 5-FU, LV, irinotecan (FOLFIRI) and 
bevacizumab was started. The patient has no evidence 
of progression for 7 months after the second relapse.
Case 2. A 51-year old male patient was admitted 
with 2 months of constipation and hematochezia. He 
was diagnosed as having rectal adenocarcinoma with 
bilateral lung metastasis and a solitary nodular lesion 
(1.8 x 1.5  cm) in the upper pole of right kidney. Renal 
mass SUVmax was 13.1 on 18-FDG-PET-CT (Fig. 3). 
Renal aspiration biopsy was performed to determine 
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Fig. 1. Focal necrosis and atypical prismatic tumor cells with 
abortive organization, hematoxylin and eosin staining — 10X 
(a), 40X (b)
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whether solitary renal mass was a synchronous renal 
cell carcinoma or rectal adenocarcinoma metasta-
sis to the kidney. Cytology of renal mass revealed 
colorectal adenocarcinoma metastasis (Fig. 4, a, b). 
He was given FOLFIRI plus bevacizumab. Though the 
CEA level decreased from 60.4 ng/mL to 3.93 ng/mL 
after 6 cycles of chemotherapy, lung and renal lesions 
remained stable on CT. Five months following the 
last cycle of chemotherapy, metastatic lesion at left 
sacroiliac joint and corpus of the second vertebrae 
were diagnosed when he presented with pain on his 
left hip radiating to left leg. He was given 2000 cGy of 
radiotherapy to those lesions which relieved his pain. 
Presently, he is at the ninth month of his follow-up.
Fig. 2. Metastatic lesion in the splenic localization (arrow) on 
18-FDG-PET-CT at second relapse (SUVmax = 11.7)
Fig. 3. A solitary nodular lesion with a dimension of 18 x 15 mm 
in the upper pole of right kidney on 18-FDG-PET-CT (SUVmax 
= 13.1)
Atypical metastasis of colon cancer may occur 
after many years from primary cancer diagnosis [2]. 
Splenic and renal metastases are very rare [2–4]. The 
rarity of splenic metastasis was attributed to anatomic 
characteristics like the sharp angle of the splenic ar-
tery with the celiac axis, rhythmic contractions by the 
sinusoids and immune surveillance of the reticuloen-
dothelial system [5].
The splenic metastasis in our case was located 
just beneath the capsule. Afferent lymphatics are 
present only in the capsular, subcapsular and tra-
becular regions of the spleen. It was postulated that 
this may explain the subcapsular location of splenic 
metastasis [6].
Splenectomy should be the treatment of choice for 
isolated splenic metastasis [5]. Though chemotherapy 
following splenectomy may be preferred, the evidence 
in the literature is inadequate to lead a definite con-
clusion related to its efficacy. Our patient was given 
FOLFIRI plus bevacizumab following splenectomy 
because of his relatively young age and good perfor-
mance status. Follow-up in our case is not long enough 
to comment on the role of chemotherapy.
a
b
Fig. 4. Tumor infiltration including discohesive cells. Tu-
mor  ce l ls  had large,  hyperchromat ic  and moder-
ately differentiated pleomorphic nuclei with cyanophil-
ic cytoplasm (May-Grünwald Giemsa staining, 400X)
Solitary nodular renal lesions are generally thought 
to be primary renal carcinoma. Multiple lung metas-
tases in addition to a solitary renal mass and multiple 
lung metastases as in our case necessitate a renal 
biopsy to differentiate these two primaries. Though the 
prognosis in both situations is dismal, the treatments 
of these primaries are specific which rationalizes the 
renal biopsy procedure.
Positive PET scans in both cases suggest a con-
tributory role of it in distinguishing metastasis from 
benign lesions.
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